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C A N C E R
Identification of human CD4+ T cell populations 
with distinct antitumor activity
Michelle H. Nelson1,2*, Hannah M. Knochelmann1,2*, Stefanie R. Bailey1,2, Logan W. Huff1,2,  
Jacob S. Bowers1,2, Kinga Majchrzak-Kuligowska1,2, Megan M. Wyatt1,2, Mark P. Rubinstein1,3, 
Shikhar Mehrotra1,3, Michael I. Nishimura4, Kent E. Armeson5, Paul G. Giresi6, Michael J. Zilliox7, 
Hal E. Broxmeyer8, Chrystal M. Paulos1,2†‡
How naturally arising human CD4+ T helper subsets affect cancer immunotherapy is unclear. We reported that human 
CD4+CD26high T cells elicit potent immunity against solid tumors. As CD26high T cells are often categorized as TH17 
cells for their IL-17 production and high CD26 expression, we posited these populations would have similar 
molecular properties. Here, we reveal that CD26high T cells are epigenetically and transcriptionally distinct from 
TH17 cells. Of clinical importance, CD26high and TH17 cells engineered with a chimeric antigen receptor (CAR) 
regressed large human tumors to a greater extent than enriched TH1 or TH2 cells. Only human CD26high T cells 
mediated curative responses, even when redirected with a suboptimal CAR and without aid by CD8+ CAR T cells. 
CD26high T cells cosecreted effector cytokines, produced cytotoxic molecules, and persisted long term. Collectively, 
our work underscores the promise of CD4+ T cell populations to improve durability of solid tumor therapies.
INTRODUCTION
CD26 is a surface glycoprotein expressed on various cell types, in-
cluding fibroblasts, epithelial, and immune cells (1). CD26 has many 
properties that could influence T cell function, including enzymatic 
cleavage of chemokines that regulate migration (2) to costimulation 
via caveolin-1 (3, 4). CD26+ T cells have been associated with exac-
erbating various autoimmune manifestations and augmenting anti-
tumor immunity (5–9). We reported that CD26 distinguishes three 
human CD4+ T cell subsets with varying degrees of responsiveness to 
tumors: one with regulatory properties (CD26neg), one with a naïve/
central memory phenotype (CD26int), and one with a durable stem 
memory profile (CD26high) (9). Adoptively transferred CD26high T cells 
engineered with chimeric antigen receptors (CARs) persisted and re-
gressed difficult-to-treat malignancies superior to CD26neg T cells and, 
unexpectedly, slightly better than naïve CD26int T cells. CD26high T cells 
secreted T helper cell 17 (TH17) cytokines, including interleukin- 
17A (IL-17A). These findings suggest CD4+CD26high T cells are 
promising for immunotherapies.
Yet, the clinical potential of naturally arising human CD4+ T helper 
subsets sorted from the peripheral blood via classic surface markers 
and engineered with a CAR has yet to be elucidated. The potency of 
murine TH17 cells over TH1 or TH2 cells in tumor immunity has 
been reported by many groups (10–13). However, the impact of human 
TH17 cells in the context of adoptive T cell transfer (ACT) therapy 
has not been fully explored. Given that CD26high cells express 
master transcription factor (TF) RORt and produce IL-17 (14), we 
postulated that human CD26high T cells would regress tumors to the 
same extent as classic TH17 cells (i.e., CCR4+CCR6+CD4+) relative to 
other CD4+ subsets when redirected with a CAR and infused into 
hosts bearing human tumors (15).
After deep sequencing and direct functional analysis of these sub-
sets, we report that CD26high T cells are molecularly and functionally 
distinct from TH17 cells. While both CD26high and TH17 cells were 
therapeutic in murine models, human CD26high T cells mediated du-
rable, relapse-free immunity, while bulk CD4, TH1, TH2, or TH17 cell 
therapies elicited only transient delays in human tumor growth. Human 
CD26high T cells demonstrated the highest engraftment and persistence 
in the peripheral blood and in tumors. Additional investigation re-
vealed that IL-17 and high surface CD26 were not required for tumor 
regression nor were cotransferred CD8+ T cells, suggesting that 
unique molecular and epigenetic properties may play a role in the 
potency of human CD26high T cells. This paper represents an im-
portant advancement in our understanding of targeting human 
CD4+ T cell subsets to tumors and has profound implications for 
future cancer immunotherapies.
RESULTS
CD26high T cells have a dynamic cytokine profile
We reported that CD4+ T cells expressing high CD26 levels (termed 
CD26high T cells) secrete IL-17A and elicit potent tumor immunity 
when redirected with a CAR compared with sorted CD26int or CD26low 
T cells (9). While CD26high T cells are categorized as TH17 cells, the 
functional profile of sorted human CD26high T cells compared with 
classic TH17 cells and other known helper subsets has not been for-
mally tested. Given the abundance of IL-17 produced by CD26high 
T cells and the reported high CD26 expression on TH17 cells (14), we 
suspected that CD26high T cells would have a similar cytokine pro-
file as classic TH17 cells. To first address this question, we measured 
the level and type of cytokines produced by various CD4+ subsets. 
These subsets were sorted from the peripheral blood of healthy 
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Fig. 1. CD4+CD26high T cells have a dynamic cytokine profile. (A) CD4+ subset sorting scheme. CD4+ lymphocytes were negatively isolated using magnetic beads from 
normal donor peripheral blood lymphocytes (PBLs). TH17 cells were sorted from the CCR6+CCR4+ gate. TH1 and TH2 cells are both CCR6− and subsequently sorted via 
CXCR3 or CCR4, respectively. CD26high cells were sorted independently on the basis of CD26 expression. (B) Chemokine receptor profile after sort. (C) CD4+ T cell subsets 
were stimulated with CD3/inducible costimulator (ICOS) beads at a ratio of 1 bead:10 T cells and expanded in IL-2 (100 IU/ml). Ten days following activation, the five 
different cell subsets were examined for their intracellular cytokine production. Dot plot representation of IL-17, interferon- (IFN-), IL-4, and IL-22 expression by flow 
cytometry. (D) Graphical representation of at least eight normal donors from independent experiments demonstrating IFN- and IL-17 single and double producing cells 
by flow cytometry. (E) Graphical representation of 10 normal donors demonstrating cytokine-producing cells by flow cytometry. Two to three replicates each. Analysis of 
variance (ANOVA), Tukey’s post hoc comparisons; *P < 0.05, **P < 0.01, and ***P < 0.001. (F) Cells were gated on cytokine-producing cells to quantify cells that produced 
between one and five cytokines simultaneously. Cytokines of interest were IL-17, IFN-, IL-2, IL-22, and tumor necrosis factor– (TNF-). Representative of five experiments.
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individuals via extracellular markers (Fig. 1A) (15). This sort yielded 
TH1 (CXCR3+CCR4−CCR6−), TH2 (CXCR3−CCR4+CCR6−), TH17 
(CCR4+CCR6+CXCR3+/−), and CD26high T cells with high purity 
(>90%). Flow cytometry validated that enriched TH1 cells expressed 
CXCR3, while TH2 cells expressed CCR4, and TH17 cells coexpressed 
CCR4 and CCR6. CD26high T cells also expressed high CXCR3 and CCR6 
but nominal CCR4 on their surface (Fig. 1B). As previously reported, 
TH17 cells expressed more CD26 than other subsets (Fig. 1B) (14).
After assessing cytokine production, we found that CD26high 
T cells were not restricted to a TH17-like functional profile (Fig. 1C). 
Instead, CD26high T cells secreted comparable amounts of IL-17A 
and greater levels of interferon- (IFN-) and IL-22 than TH17 cells 
(Fig. 1, C to E). CD26high T cells produced nearly as much IFN- as 
TH1 cells but less IL-4 than TH2 cells. We consistently observed this 
functional pattern in CD26high T cells from several healthy individ-
uals (Fig. 1C to E). On a per-cell basis, these various CD4+ T cell 
populations were assayed for their capacity to secrete up to five cyto-
kines at once, including IL-17A, IL-22, IFN-, tumor necrosis factor– 
(TNF-), and IL-2 (Fig. 1F). Only CD26high T cells secreted four (36%) 
to five (7%) cytokines simultaneously, while bulk CD4+, TH1, TH2, 
and TH17 cells, at most, cosecreted three cytokines (Fig. 1F).
As CD26high T cells express more IL-23R mRNA than CD26low 
or CD26int T cells (9, 14), we tested whether this cytokine would 
induce TH1 or TH17 cells to cosecrete elevated IL-17A and IFN- to 
the levels mediated by CD26high T cells. While IL-23 did not pro-
voke TH1 cells to cosecrete IL-17A and IFN-, it did increase the 
coproduction of these two cytokines by TH17 cells (fig. S1, A and B), 
albeit not to the extent of CD26high T cells. Overall, CD26high T cells 
have a functional profile distinct from other CD4+ T subsets and are 
more dynamic than classic TH17 cells.
CD26high T cells display a unique chromatin landscape
Given the functional profile of CD26high T cells, we hypothesized 
that the epigenetic landscape of these cells at resting state would be 
different from that of TH17 cells. To test this idea, we sorted naïve, 
TH1, TH2, TH17, and CD26high T cells from the blood of five differ-
ent healthy donors and profiled their chromatin accessibility with 
assay for transposase-accessible chromatin with high-throughput se-
quencing (ATAC-seq). CD26high T cells contained peaks displaying 
enhancer-accessible regions near various TFs known to direct TH1 
(such as Tbx21 and EOMES) and TH17 (RORC) cell lineage devel-
opment while displaying suppressor regions near TF genes known 
to regulate TH2 development, such as GATA3 (Fig. 2, A and B). 
While Tbx21 and EOMES were more accessible in both TH1 and 
CD26high T cells, they were repressed in naïve, TH2, and TH17 cells 
(Fig. 2B). Moreover, a core of other accessible regions in TH1-related 
TFs, such as MGA, STAT2, STAT1, and STAT5A, were pronounced 
in TH1 and CD26high T cells (Fig. 2A). As expected, accessible re-
gions surrounding GATA3 were enhanced in TH2 cells and TH17 
cells. Other enhancer accessible regions surrounding TH2-like TFs, 
such as GATA1, GATA2, GATA4, GATA5, GATA6, PAX4, YY1, 
PITX2, and GFI1, were distinguished in TH2 and TH17 cells (Fig. 2A). 
Similar to TH17 cells, chromatin-accessible regions near the RORA, 
RORC, and STAT3 loci were enhanced in CD26high T cells but sup-
pressed in naïve, TH1, and TH2 cells (Fig. 2, A and B). TH1 cells more 
closely aligned with the epigenetic landscape of naïve cells, as they both 
expressed accessible chromatin regions neighboring TFs in the stem 
and development pathways, including TCF7, LEF1, CTCF, DNMT1, 
and ZFP161 (Fig. 2A). Yet, certain accessible regions in naïve cells were 
also heightened in both CD26high and TH1 subsets, including STAT1, 
STAT2, IRF1, IRF2, IRF3, IRF5, IRF7, IRF8, and ZNF683 (Fig. 2A).
Despite overlap with TH1 and TH17 cells, CD26high T cells had a 
unique set of differentially accessible elements relative to other sub-
sets. Open accessible regions in the CCAAT/enhancer-binding pro-
tein family (C/EBP), which function as TFs in processes including 
cell differentiation, motility, and metabolism were among the most 
unique and differentially expressed in CD26high T cells (Fig.  2, A 
and B). Along with CEBPs, ELK3, important for cell migration and 
invasion, and RUNX, which promotes memory cell formation, were 
enhanced in CD26high T cells. Principal components analysis of the 
genome-wide open chromatin landscape of these 25 samples showed 
that CD26high T cells cluster separately from naïve, TH1, TH2, and TH17 
cells (Fig. 2C). We verified the distinct characteristics of CD26high 
versus TH17 cells using gene array (fig. S2, A and B). Further, as 
helper subsets have been reported to express a particular  T cell 
receptor (TCR) repertoire (16), we defined the frequency and like-
lihood of TCR-clonotype overlap between various sorted subsets 
and found nominal overlap between CD26high cells and other helper 
subsets (Fig. 2D and fig. S2C). Collectively, we conclude that the 
epigenetic landscape and TCR repertoire of CD26high cells differ 
substantially from that of classic CD4+ subsets.
Single-cell sequencing reveals that CD26high T cells are 
molecularly unique from TH17 cells
Single-cell transcriptome analysis also supported that CD26high 
T cells are distinguished from TH17 cells on the basis of differential 
clustering from that of bulk CD4+ and TH17 cells (Fig. 3A). A clus-
ter of regulatory T cell (Treg)–like cells was present within the sorted 
TH17 population (Fig. 3B), as demonstrated by heightened FOXP3, 
IL2RA, and TIGIT and reduced IL7R transcript, but was not found 
within CD26high T cells. A small cluster of TH1-like cells was identi-
fied within the sorted bulk CD4+ population, as indicated by elevated 
TBX21 and CXCR3 but nominal transcripts associated with TH17 or 
Treg cells, such as CXCR6, CCR6, CCR4, RORC, and FOXP3. Tran-
scripts associated with less differentiated populations, composed of 
naïve or central memory cells, including SELL, CCR7, and CD27, 
were expressed at slightly higher levels in bulk CD4+ cells than other 
populations. Conversely, IL2RB and IL15RA were lower on bulk CD4+ 
T cells compared with other populations. In concurrence with their 
chromatin accessibility, CEBPD transcripts were elevated in CD26high 
T cells compared with bulk CD4+ or TH17 cells. Together, these data 
suggest that CD26high T cells are unique from TH17 cells, yet their rel-
ative clinical potential in cancer immunotherapy remained unknown.
CD26high T cells demonstrate enhanced tumor immunity 
compared with other helper subsets
We reported that TH17 cells cosecrete more IL-17A and IFN- after 
expansion with CD3/inducible costimulator (ICOS) versus CD3/
CD28 activator beads (17). While CD3/CD28 beads are mainly used 
to manufacture CAR T cell products, we and others (18) have found 
that the frequency of Tregs is augmented in CD4+ cultures expanded 
with CD3/CD28 beads relative to CD3/ICOS beads (fig. S3A). More-
over, TH1, TH17, and CD26high cells secreted elevated IFN- and/or 
IL-17A when expanded with CD3/ICOS beads compared with CD3/
CD28 beads (fig. S3B). Therefore, we elected to use the CD3/ICOS 
bead expansion platform to investigate the relative antitumor po-
tential of various sorted CD4+ T helper populations in vivo. Specif-
ically, as in fig. S4A, we engineered sorted TH1, TH2, TH17, CD26high, 
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and bulk CD4+ T cells to express mesothelin-specific CAR (meso- 
CAR) and infused them into NSG (nonobese diabetic, severe com-
bined immunodeficient gamma chain knockout) mice bearing large 
established mesothelioma tumors. Note that we used a first-generation 
meso-CAR, reported by our colleagues to be less therapeutic than 
second-generation meso-CARs (19), as we surmised this approach 
would generate a treatment window to address whether CD26high 
T cells lyse tumor to a greater extent than other subsets. CD8+ T cells 
(10-day expanded) were also redirected with this first-generation CAR 
and coinfused at equal numbers with these various CAR-CD4+ sub-
sets (Fig. 4A). CD26high T cells eradicated tumors, while TH17 cells 
only regressed tumors short term (Fig.  4,  B  and  C). Yet, both 
CD26high and TH17 cells were more effective than TH1, TH2, or bulk 
CD4+ T cells (Fig. 4, B and C). Ultimately, mice treated with CD26high 
T cells survived significantly longer (Fig. 4D), which was associated 
with higher CD4+ and CD8+ CAR T cell engraftment and persistence 
compared with other subsets (Fig. 4, E and F). Moreover, cotrans-
ferred CD4+CD26high cells, and TH17 cells to a lesser extent, improved 
the function of CD8+ CAR T cells, as persistence of CD8+IFN-+ 
and CD8+IFN-+/IL-2+/TNF-+ CAR T was elevated in the spleen 
(fig. S4, B to D).
As immunity via CAR therapy was enhanced using TH17 or 
CD26high populations over other subsets, we anticipated that IL-17A 
or CD26 itself regulated their efficacy. However, persisting TH17 
and CD26high CAR T cells did not produce IL-17A but rather secreted 


































Fig. 2. The epigenetic and molecular signature of CD26high T cells are unique. (A) ATAC-seq analysis describing chromatin accessibility in FACS (fluorescence-activated 
cell sorting)–sorted CD4+ subsets (naïve, TH1, TH2, TH17, and CD26high) organized by TF networks known to describe TH1, TH2, TH17, and naïve subsets. Accessible transcrip-
tion regions unique to CD26high T cells are also shown. Compiled from five healthy donors. (B) UCSC genome browser tracks for sorted CD4+ subsets around classical 
T helper TFs from ATAC-seq analysis. (C) ATAC-seq principal components analysis of sorted T cell subsets analyzed at resting state. n = 5 donors. (D)  T cell receptor (TCR) 
sequencing of CD26high, TH17, and TH1 cells sorted from peripheral blood of healthy donors demonstrates unique or shared clonotypes. Venn diagram illustrates percent-
age of unique or shared TCR sequences. The relative frequencies (standardized to sum to 1.0): CD26high only = 0.237, TH1 only = 0.487, TH17 only = 0.196, CD26high and 
TH1 = 0.041, CD26high and TH17 = 0.020, TH1 and TH17 = 0.015, and all three = 0.004, log-linear model.
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responsible for their maintenance (fig. S4E). Thus, we next tested 
whether CD26 was critical by knocking it out in CAR T cells via 
CRISPR-Cas9–mediated genome engineering. To capitalize on cell 
yield needed for these multiple genetic manipulations, we polarized 
bulk CD4+ T cells to the TH17 phenotype. These cells were activated, 
engineered with meso-CAR, knocked out of CD26, and sorted to 
obtain a pure CD26− population (fig. S5, A to C). Neither cytokine 
production nor tumor immunity was affected by loss of CD26 (fig. S5, 
D to F). Overall, these data imply that IL-17 and CD26 may not be 
critical to effective antitumor responses mediated by transferred 
TH17 or CD26high T cells.
We also found that murine tyrosinase-related protein 1 (TRP-1) 
CD26high and TH17 cells stalled the growth of poorly immunogenic 
B16F10 melanoma to a greater extent than TRP-1 TH1 cells in mice 
(fig. S6A). Moreover, murine CD26high T cell therapy enhanced the 
survival of mice compared with TH1 cells but was not markedly dif-
ferent from TH17 cells (fig. S6B). Our data underscore in two dis-
tinct solid tumor models the promise of TH17 and particularly human 
CD26high T cells in immunotherapy.
CD4+CD26high T cells do not require CD8+ CAR T cells 
for persistence in the tumor
Given the potency of human meso-CAR CD26high T cell therapy 
against mesothelioma, we next sought to uncover whether cotrans-
ferred CD8+ T cells were important for long-term survival in mice. 
Because of the polyfunctionality of CD26high cells (Fig. 1), along 
with their heightened cytotoxic capacity (fig. S7), we posited that 
they may not require CD8+ CAR T cells. To address this question, 
CD4+CD26high CAR T cells were transferred with or without CD8+ 
CAR T cells into mice bearing M108 tumors (fig. S8, A and B). In-
deed, CD4+CD26high CAR T cells did not require the presence of 
CD8+ CAR T cells to regress tumors, and CD8+ CAR T cells alone 
were not therapeutic long term (fig. S8B).
Last, we questioned whether the CAR signaling in CD4+CD26high 
cells was critical to improve CD8+ CAR T cell persistence in the tumor 
or whether their presence alone (i.e., redirected with a nonsignaling 
CAR) could support CD8+ CAR T cells. To address this question, 
CD8+ and CD26high T cells were redirected with either a full-length 
signaling meso-CAR- or a truncated TCR domain without sig-
naling capability () but could still recognize mesothelin and ana-
lyzed their presence in tumors. We found that meso--CD26high 
cells, either coinfused with meso--CD8+ or with meso--CD8+ 
T cells, promoted CD45+ immune persistence in M108 tumors 
84 days after transfer (fig. S8C). Conversely, CAR T cells did not per-
sist whether transferred with meso--CD26high cells. Collectively, 
our work reveals that meso-CAR CD4+CD26high cells are cytotoxic, 
require CD3 signaling to survive long term, and regress tumors in 
the absence of conventional meso-CAR CD8+ T cells.
DISCUSSION
CAR T cells are therapeutic in patients with hematological malig-
nancies but have been largely ineffective in individuals with solid 
tumors, owing in part to the oppressive tumor microenvironment 
and poor persistence. Many efforts for overcoming these obstacles 
include modulating T cell trafficking, cytokine delivery, costimula-
tion, and improving cell persistence among other strategies reviewed 
previously (20). CD4+ T cells help cytotoxic CD8+ T cells and, when 
CAR engineered, improve longevity of responses against hemato-
logical malignancies (21, 22). Here, we reveal that naturally arising 
CD4+ T cell subsets in the peripheral blood differentially affect effi-
cacy of CAR therapy for solid tumors. For the first time, we demon-
strate that CD4+CD26high T cells redirected with CAR have enhanced 
functional and antitumor activity versus classic human subsets (TH1, 
TH2, and TH17) or unselected CD4+ T cells, as summarized visually 
in Fig. 5.
CD26high T cells derived from the peripheral blood of healthy 
individuals were polyfunctional, cosecreting elevated IL-17A and 
IFN-, while classic TH1, TH2, or TH17 cells lacked this dynamic 
profile. Moreover, CD26high T cells had epigenetic and molecular 
properties distinguishing them from TH17 or TH1 cells. Of clinical 





Fig. 3. CD4+CD26high T cells are distinguished from TH17 cells via single-cell 
sequencing. Total CD4+, CD26high, and TH17 cell subsets were sorted from the pe-
ripheral blood of healthy donors, and ~3000 cells were assayed by single-cell RNA 
sequencing. (A) Data were analyzed by t-distributed stochastic neighbor embedding 
(t-SNE). (B) t-SNE plot overlaid with mRNA expression of chemokine receptors, TFs, 
memory markers, and cytokine receptors. Representative of three healthy donors.
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Fig. 4. Human CD26high T cells ablate large human tumors and persist relative to other CD4+ T cell subsets. (A) ACT schematic. TH1 (CXCR3+), TH2 (CCR4+), TH17 
(CCR4+/CCR6+), CD26high, or bulk CD4+ cells were sorted from normal donor PBL and expanded with CD3/ICOS beads at a 1 bead:10 T cell ratio. Cells were transduced 
with a first-generation mesothelin-specific CD3 CAR and expanded with IL-2. NSG mice bearing mesothelioma were treated with 4 × 106 transduced, sorted CD4+ cells + 
4 × 106 transduced CD8+ cells, and 50,000 IU of IL-2 was given to each mouse daily for 3 days. (B) Single-tumor curves overlaid with average curve (red) and (C) average tumor 
curves of six to nine mice per group. All groups were significantly different from non-treated mice (NT), P < 0.005. CD4 versus TH1, NS; CD4 versus TH2, **P = 0.0015; CD4 
versus TH17, **P = 0.0035; CD4 versus CD26high, ***P = 0.0003; TH17 versus CD26high, **P = 0.008; polynomial regression. (D) The percentage of mice surviving with tumor 
size below the 200-mm2 threshold. Log-rank test. (E) Engraftment and persistence of CAR+ T cells in the peripheral blood at days 20 (D20) and 38 (D38) after ACT. n = 6 to 
8 mice per group. X denotes group was at end point before bleed. (F) Spleens were analyzed by flow cytometry for the percentage and total number of CD3+CAR+CD4+ 
or CD8+ cells at day 68 (TH17 and CD26high) or group end point (CD4, TH1, and TH2). n = 4 to 6 mice per group. (E and F) ANOVA, Tukey’s post hoc comparisons; **P < 0.01, 
***P < 0.001, and ****P < 0.0001.
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mice when ex vivo engineered with CAR, while TH17 cell therapies 
transiently regressed tumors, and bulk CD4+, TH1, or TH2 subsets 
were largely ineffective.
As TH17 cells express the highest CD26 relative to other subsets, we 
anticipated that CD26 or IL-17 may be driving antitumor proper-
ties in TH17/CD26high T cell therapies. Unexpectedly, neither of these 
factors appeared critical to delay tumor growth. CRISPR-Cas9– 
mediated knockout of CD26  in TH17 cells delayed the onset of 
tumor regression but ultimately did not affect the overall antitumor 
response in mice. In addition, CAR TH17 or CD26high T cells 
persisting for several months after ACT did not maintain IL-17 
expression but continued to produce IFN-. These data suggest 
that IFN-, rather than IL-17, is more important to immunity 
elicited by TH17 or CD26high T cells, a concept supported by other 
models transferring murine IL-17–producing tumor-specific T cells 
(10, 23).
While CD26 may not directly affect tumor immunity from CD4+ 
CAR T cells in our NSG human xenograft model, it remains possible 
that CD26 marks lymphocytes with the ability to persist. CD26high 
T cells engrafted in the peripheral blood and tissues at early time points 
after adoptive transfer and remained detectable at the tumor bed for 
several months. Properties such as their stemness profile, polyfunc-
tionality, or, perhaps, resistance to the oppressive microenvironment 
may permit their survival within the tumor. Alternately, traffick-
ing of CD26high T cells may support their accumulation at the 
tumor as they express higher CCR2 and CXCR6 relative to other 
helper subsets (9, 24). Yet, we remain cautious to dismiss the impact 
of CD26 itself in tumor immunity, as future work will test whether 
CD26 overexpression is able to improve subtherapeutic T cell 
products and address this concept in model systems with intact 
host immunity.
Beyond CD26 and IL-17, other factors within the cell product 
may differentiate CD26high from TH17 cell therapies. CD26high T cells 
produced more cytotoxic molecules than TH17 and bulk CD4+ T cells 
and did not require CD8+ T cells to instill immunity, suggesting an 
ability to directly lyse tumor in vivo. Further investigation revealed 
that sorting TH17 cells by CCR4+CCR6+ yielded an IL-17+ popula-
tion containing FoxP3+IL-2Rhigh Tregs, which was not present when 
sorting CD26high T cells. The enrichment of polyfunctional and cyto-
toxic over regulatory properties in CD26high T cells may support their 
durable responses, which provides insights on sorting functional 
CD4+ cells for cancer immunotherapies.
Last, while our work shows that enriching CD4+ T cell subsets 
can improve suboptimal CAR constructs lacking costimulation, it 
will be important to clinically elucidate the impact of costimulatory 
domains and cytokine support on the persistence and durability of 
CD4+ T cell populations. Expanding the CD4+ CAR product with 
CD3/ICOS activator beads rather than clinically standard CD3/CD28 
beads enhanced IFN- and/or IL-17A production by T cell subsets 
while diminishing Treg populations. Indeed, cotransfer of CD4+ CAR 
T cells containing ICOS domains improves the persistence of CD8+ 
T cells equipped with CD28 or 4-1BB domains (25). These data sug-
gest that ICOS costimulation may enhance engraftment, persistence, 
and tumor immunity of CD4+ CAR T cell products relative to tradi-
tional CD3/CD28 bead activation. In addition to costimulation, cyto-
kine support may play an important role for CD4+ subsets after 
adoptive transfer. Although all CD4+ subsets described herein pro-







persistence persistence, cytolytic 
N-γ
IFN-γ
Fig. 5. CD4+CD26high T cells have distinct antitumor and molecular properties relative to other helper subsets. CD26high T cells have been described herein for use 
in ACT therapy. These cells produce heightened levels of cytokines including IL-17, IFN-, IL-22, and IL-2 and can cosecrete these cytokines. CD26high T cells have a distinct 
chromatin landscape with accessible regions near RORC, Tbx21, CEBP, and RUNX TFs and have a unique transcriptional signature. These cells are cytotoxic, multifunctional, 
and inflammatory. Overall, CD26high T cells persist and regress tumors to a remarkably greater extent than other CD4+ T cells in vivo and represent a distinct CD4+ helper 
population with potent antitumor properties.
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model, which was used on the basis of preclinical work demonstrating 
the ability of IL-2 to improve function of tumor-specific T cells (26). 
RNA sequencing of human CD4+ subsets revealed that CD26high 
and TH17 cells expressed elevated IL-2R and IL-2R transcripts, 
while most CD4 cells expressed IL-7R. While it remains possible 
that IL-2 promotes the engraftment of TH17 and CD26high cells over 
others based on their surface receptor profile, it is not likely that 
exogenous IL-2 is critical for long-term persistence, as this cytokine 
was only provided for the first 3 days after ACT. We acknowledge 
that other costimulatory molecules or cytokines may differentially 
affect CD4+ cell subsets, as tested here, a concept worth addressing 
to yield the most therapeutic T cell products for patients with a va-
riety of malignancies.
There are many implications from our findings given the signif-
icant antitumor responses mediated by CD26high T cells in a mouse 
model of large established human mesothelioma. The epigenetic and 
molecular landscape of these helper subsets will permit investigators 
to address previously unexplored questions regarding their func-
tion in the immune system. Future work to translate, target, and 
redirect these cells to eradicate tumors or target cells inducing 
autoimmunity in the clinic could provide new treatment options 
for a vast array of diseases. Clinical trial designs are now underway 
based on our findings to evaluate the potential of CD4+CD26high 
T cells in patients.
METHODS
Study design
Sample size: As these experiments were exploratory, there was no 
estimation to base the effective sample size; therefore, we based our 
animal studies using sample sizes ≥5. Rules for stopping data col-
lection: Experimental end points were designated before study exe-
cution. Tumor control studies were conducted over ~70 days. Data 
inclusion/exclusion: For experiments reported here, animals were 
only excluded if tumors were very small or not measurable, a rule 
established prospectively before any therapy initiation. Outliers: 
Outliers were reported. End points: Tumor end point was reached 
when tumor area exceeded 400 mm2. Remaining mice were eutha-
nized, and spleens were harvested when more than half of the mice 
in a group reached tumor end point. Randomization: Before therapy, 
mice were randomized on the basis of tumor size. Blinding: Tumors 
were measured using L × W measurements via calipers by person-
nel blinded to the treatment group.
Statistical analysis
Tumor area results were transformed using the natural logarithm 
for data analysis. Mixed-effects linear regression models with a ran-
dom component to account for the correlation of the repeated mea-
sure within a mouse were used to estimate tumor area over time. In 
circumstances where linearity assumptions were not met, polynomial 
regression models were used (27). Linear combinations of the result-
ing model coefficients were used to construct estimates for the slope 
differences with 95% confidence intervals (CIs), where applicable. For 
polynomial models, estimates were constructed for the differences 
in area between groups on the last day where at least one mouse was 
alive in all groups. Experiments with multiple groups were analyzed 
using one-way analysis of variance (ANOVA) with postcomparison 
of all pairwise groups using Tukey’s range test. Experiments compar-
ing two groups were analyzed using a Student’s t test. The center values 
are the means. TCR sequencing analysis was based on the log-linear 
model, and the “relative risks” were calculated with a 95% CI.
Subset isolation
Deidentified, normal human donor peripheral blood cells were pur-
chased as a buffy coat (Plasma Consultants) or leukapheresis (Re-
search Blood Components). Peripheral blood lymphocytes (PBLs) 
were enriched using lymphocyte separation media (Mediatech). 
CD4+ T cells were negatively isolated using magnetic bead separa-
tion (Dynabeads, Invitrogen) and plated in culture medium with a 
low concentration of rhIL-2 [20 IU/ml; National Institutes of Health 
(NIH) repository] overnight. For in vivo studies, CD8+ T cells were 
positively isolated before the enrichment of CD4+ T cells. The fol-
lowing morning, CD4+ T cells were stained using PE-CD26 (BA5b), 
AlexaFluor647-CXCR3 (G025H7), PECy7-CCR6 (G034E3, BioLegend), 
FITC-CCR4 (205410, R&D Systems), and APCCy7-CD4 (OKT4, BD 
Pharmingen). Cells were sorted on the basis of the following gating 
strategies: bulk CD4:CD4+; TH1:CD4+CCR6−CCR4−CXCR3+; TH2: 
CD4+CCR6−CCR4+CXCR3−; TH17:CD4+CCR6+CCR4+; and CD26: 
CD4+CD26high. Cells were sorted on a BD FACSAria IIu cell sorter 
or on a Beckman MoFlo Astrios high-speed cell sorter.
T cell culture
Human: T cell subsets were expanded in RPMI 1640 culture medium 
supplemented with nonessential amino acids, l-glutamine, sodium 
pyruvate, Hepes, penicillin/streptomycin, -mercaptoethanol, and fetal 
bovine serum. Cells were cultured at either a 1:1 or 1:10 bead–to– 
T cell ratio. Magnetic beads (Dynabeads, Life Technologies) coated 
with antibodies to CD3 (OKT3) and/or ICOS (ISA-3, eBioscience) 
or CD28 (CD28.2, BioLegend) were produced in the laboratory ac-
cording to the manufacturers’ protocols. rhIL-2 (100 IU/ml; NIH 
repository) was added on day 2, and media were replaced as needed. 
For CRISPR experiments, bulk human CD4+ cells were polarized to 
TH17 phenotype using a cocktail of cytokines [hIL-6 (10 ng/ml), 
hIL-1 (10 ng/ml), hIL-23 (20 ng/ml), and IFN- and IL-4 (5 g/ml)].
T cell transduction
To generate mesothelin-specific T cells, CD3/ICOS-activated, sorted 
CD4+ and bulk CD8+ T cells were transduced with a lentiviral vector 
encoding a chimeric anti-mesothelin single-chain variable frag-
ment fusion protein containing the TCR signaling domain (first- 
generation meso-CAR) or a truncated CD3 nonsignaling domain 
() that was generated as described previously (19). CAR expres-
sion was determined using a flow cytometry antibody specific for the 
murine F(ab')2 fragment (Jackson ImmunoResearch, 115-606-006). 
Cells were normalized for CAR expression before adoptive transfer.
Flow cytometry
For intracellular staining data, cells were stimulated with PMA 
(phorbol 12-myristate 13-acetate)/ionomycin. After 1 hour, Monensin 
(BioLegend) was added and incubated for another 3 hours. Following 
surface staining, intracellular staining with antibodies was performed 
according to the manufacturer’s protocol using Fix and Perm buffers 
(BioLegend). Data were acquired on a BD FACSVerse or LSRII X-20 (BD 
Biosciences) and analyzed using the FlowJo software (BD Biosciences).
Microarray
RNA was isolated from sorted CD4+ T cells using the Qiagen RNeasy 
Mini kit and frozen. RNA was submitted to the Phalanx Biotech 
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Group for processing on their OneArray platform (San Diego, CA). 
Heat map and principal components analysis clustering: Graphing 
was performed in R (version 3.1.2) using gplots (version 2.16.0). 
Log2 values for CD4+ cells were averaged and used as baseline for 
the genes of interest. For each individual sample, the fold change 
relative to baseline was calculated, and the median value for the 
triplicates was calculated and used for generating figures.
ATAC sequencing
Sorted CD4+ T cells were cryopreserved in CryoStor and sent for 
analysis. Naïve cells were sorted on the basis of expression of CCR7 
and CD45RA. ATAC-seq was performed by Epinomics according 
to the protocol described by Buenrostro et al. (28). Fifty thousand 
sorted T cells were frozen using Cryostor CS10 freeze media (BioLife 
Solutions) and shipped on dry ice for processing and analysis to 
Epinomics (Menlo Park, CA).
TCR sequencing
Sorted T cells were centrifuged and washed in phosphate-buffered 
saline (PBS), and genomic DNA was extracted using Wizard Ge-
nomic DNA purification kit (Promega). The quantity and purity of 
genomic DNA were assessed through spectrophotometric analysis using 
NanoDrop (Thermo Fisher Scientific). Amplification of TCR genes 
was done within the laboratory using the ImmunoSEQ hsTCR kit 
(Adaptive Biotechnologies Corp., Seattle, WA) according to the 
manual. Survey sequencing of TCR was performed by the Hollings 
Cancer Center Genomics Core using the Illumina MiSeq platform.
Single-cell RNA sequencing
Sorted TH17, CD26high T cells, or bulk CD4+ T cells were cryopre-
served and sent for analysis to David H. Murdock Medical Research 
Institutes Genomics Core. Genomic DNA was analyzed using the 
Chromium Controller instrument (10X Genomics, Pleasanton, CA), 
which uses molecular barcoding to generate single-cell transcrip-
tome data (29). Sequencing of the prepared samples was performed 
with a HiSeq2500 platform (Illumina). Data were analyzed with Long 
Ranger and visualized with Loupe (10X Genomics).
Mice and tumor line
NSG mice (the Jackson laboratory) were bred at the University of 
Pennsylvania or at the Medical University of South Carolina. NSG 
mice were given ad libitum access to autoclaved food and acidified 
water. M108 xenograft tumors (gift from C. H. June), described pre-
viously (19), were tested for mycoplasma during expansion (Lonza). 
C57BL/6 and TRP-1 TCR transgenic mice (10) were purchased from 
the Jackson laboratory and housed/bred in the comparative medicine 
department at the Medical University of South Carolina Hollings 
Cancer Center (MUSC, Charleston, SC). The B16F10 melanoma 
tumor cell line was gifted by N. P. Restifo from the Surgery Branch 
of the National Cancer Institute.
CRISPR for human T cells
Primary human T cells were activated for 3 days with aCD3/ICOS 
beads before CRISPR manipulation. On day 3, cells were debeaded 
and rested for 3 hours before electroporation. Two micrograms of 
CD26-specific single-guide RNA (sgRNA) (GenScript) was com-
bined with 1 g of GeneArt Platinum Cas9 Nuclease (Thermo Fisher 
Scientific) per 1 × 106 cells and incubated for 20 min at room tem-
perature. During this time, cells were washed three times in PBS 
and then resuspended in T buffer (Neon Transfection Kit, Thermo 
Fisher Scientific) at 4 × 106 cells/100 l. The sgRNA-Cas9 mixture 
was then added to the cells, followed by electroporation (2250 V, 
20 ms, 1 pulse) using the Neon Transfection system (Thermo Fisher 
Scientific). Control cells were electroporated without the addition 
of sgRNA-Cas9. Cells were immediately returned to culture in pre-
warmed cell media without antibiotics but containing an additional 
1% l-glutamine. Following an overnight rest, cells were resuspended 
in complete culture medium with IL-2 for normal culture.
Confocal microscopy
Human T cells were fixed in 4% paraformaldehyde at room tem-
perature for 15 min. Following centrifugation, cells were blocked in 
1% bovine serum albumin (BSA) for 20 min at room temperature. 
Cells were then centrifuged and stained with an unconjugated anti- 
CD26 primary antibody (1:50 in 1% BSA) overnight at 4°C. The 
following morning, T cells were washed with PBS and incubated in 
secondary antibody (goat--mouse AF647; BioLegend) for 1 hour 
at room temperature. After washing, cells were attached to glass 
slides using a Cytospin centrifuge and imaged using an Olympus 
Fv10i confocal microscope.
Ethics approval
Human peripheral blood was not collected specifically for the pur-
poses of this research, and all samples were distributed to the labo-
ratory in a deidentified manner. Therefore, this portion of our 
research was not subject to institutional review board (IRB) oversight. 
All animal studies were approved by the Institutional Animal Care 
and Use Committee at the Medical University of South Carolina.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/6/27/eaba7443/DC1
View/request a protocol for this paper from Bio-protocol.
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